COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2-Reference-Cited by-同舟云学术

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

Published:2023-02 Issue: Volume:56 Page:101823
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Szubert Alex J.^ORCID,Pollock Katrina M.^ORCID,Cheeseman Hannah M.,Alagaratnam Jasmini,Bern Henry,Bird Olivia,Boffito Marta,Byrne Ruth,Cole Tom,Cosgrove Catherine A.,Faust Saul N.,Fidler Sarah,Galiza Eva,Hassanin Hana,Kalyan Mohini,Libri Vincenzo,McFarlane Leon R.,Milinkovic Ana,O'Hara Jessica,Owen David R.,Owens Daniel,Pacurar Mihaela,Rampling Tommy,Skene Simon^ORCID,Winston Alan^ORCID,Woolley James,Yim Yee Ting N.,Dunn David T.,McCormack Sheena,Shattock Robin J.^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Emerging technologies for low-cost, rapid vaccine manufacture;Kis;Biotechnol J,2019

2. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice;McKay;Nat Commun,2020

3. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial;Pollock;eClinicalMedicine,2022

4. Combined skin and muscle DNA priming provides enhanced humoral responses to a human immunodeficency virus type 1 clade C envelope vaccine;Cheeseman;Hum Gene Ther,2018

5. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials;Voysey;Lancet,2021

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the design and delivery of RNA vaccines for infectious diseases;Advanced Drug Delivery Reviews;2024-10

2. The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA;Journal of Controlled Release;2024-10

3. Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo;Molecular Therapy;2024-08

4. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials;Nature Communications;2024-05-14

5. Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies;Expert Review of Vaccines;2024-05-06